Nonalcoholic fatty liver disease and fibrosis progression: The good, the bad, and the unknown

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 4, 2015, Pages 655-657

  Harrison, Stephen A ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; FOLLOW UP; GENETIC VARIABILITY; HEPATITIS C; HUMAN; INFECTION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; META ANALYSIS (TOPIC); MORTALITY; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; STAGING; SYSTEMATIC REVIEW (TOPIC); UNITED STATES; COMPLICATION; PATHOLOGY;

HUMANS; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84924955019     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.11.024     Document Type: Editorial

References (14)

1. Torres D.M., Williams C.D., Harrison S.A. Features, diagnosis and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012, 10:837-858.
2. http://stateofobesity.org/adult-obesity.
3. Singh S., Allen A.M., Wang Z., et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015, 13:643-654.
4. Kleiner D.E., Brunt E.M. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012, 32:3-13.
5. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012, 142:1592-1609.
6. Pais R., Charlotte F., Fedchuk L., et al. Asystematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. JHepatol 2013, 59:550-556.
7. Dam-Larson S., Becker U., Franzmann M.-B., et al. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol 2009, 44:1236-1243.
8. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
9. Argo C.K., Northrup P.G., Al-Osaimi A.M.S., et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. JHepatol 2009, 51:371-379.
10. Dongiovanni P., Donati B., Fares R., et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 2013, 19:6969-6978.
11. Liu Y.-L., Reeves H.L., Burt A.D., et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014, 5:4309.
12. Stepanova M., Rafiq N., Makhlouf H. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2013, 58:3017-3023.
13. Ekstedt M., Hgstrom H., Nasr P., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow up. Hepatology 2014, Epub ahead of print.
14. White D.L., Kanwal F., El-Serag H.B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012, 10:1342-1359.